




# NEOSALVARSAN

TRADE MARK  
BRAND  
NEOARSPHENAMINE  
EHRlich's ORIGINAL  
'914'

Approved for use under the V.D. Regulations, 1916, and tested in accordance with the Therapeutic Substances Act, 1925.

The ampoule body 'A' contains the Neosalvarsan, and the fluid container 'B' the necessary quantity of sterile redistilled water.



## ISO DOUBLE AMPOULE

For the immediate preparation of a sterile Solution of Neosalvarsan ready for use, by means of a few simple manipulations.

ORIGINAL PACKINGS

I (0.15 gm.)	+ 2.5 c.c.	aq. redistill. steril.
II (0.3 gm.)	+ 5.0 c.c.	
III (0.45 gm.)	+ 7.5 c.c.	
IV (0.6 gm.)	+ 10.0 c.c.	
V (0.75 gm.)	+ 10.0 c.c.	
VI (0.9 gm.)	+ 10.0 c.c.	

**BAYER PRODUCTS LTD.,**  
19 ST. DUNSTAN'S HILL,  
LONDON, E.C.3.



## THE SUBCUTANEOUS ARSPHENAMINE

# SULFARSENOL

THE ORIGINAL  
SULPHARSPHENAMINE

of Dr. LEHNHOFF-WYLD.

Manufactured by the Laboratoire de Biochimie Medicale, Paris.

Tested in accordance with the Therapeutic Substances Act, 1925, and approved for use under the V.D. Regulations, 1916.

Specific in—**SYPHILIS** in all its stages  
and **GONORRHOEAL COMPLICATIONS**


**EXTREME FACILITY OF INJECTION EITHER BY THE DEEP  
SUBCUTANEOUS OR INTRAMUSCULAR ROUTES**

Brochures giving particulars of treatment and a résumé of reports on request from

**MODERN PHARMACALS LTD.,** 12 GUILFORD STREET, LONDON, W.C.1

Telephone: Holborn 3202.

Telegrams: "Pharmacals, Holb., London."



# **TRYPARSAMIDE**

TRADE MARK

SODIUM N-PHENYLGLYCINEAMIDE P-ARSONATE

For **NEUROSYPHILIS**

especially **Tabes Dorsalis** and **General Paralysis of the Insane**.

**TRYPARSAMIDE** is of outstanding therapeutic value. Its low toxicity and high power of penetration of the central nervous system, enable intensive treatment to be carried out with highly satisfactory results.

**MAY & BAKER**

**L<sup>TD</sup>.**

**BATTERSEA, LONDON, S.W.11**